BETWEENSenomyx Inc • February 21st, 2001 • California
EXHIBIT 10.10 11099 North Torrey Pines Road La Jolla, CA 92037 EXPANSION LEASE BY AND BETWEEN Health Science Properties, Inc. and Sequana Therapeutics, Inc. TABLE OF CONTENTSLetter Agreement • March 29th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
SENOMYX, INC.Rights Agreement • February 21st, 2001 • Senomyx Inc • California
AMBRYX INC. CONSULTING AGREEMENTConsulting Agreement • February 21st, 2001 • Senomyx Inc • California
SENOMYX, INC., Issuer AND [TRUSTEE], Trustee INDENTURE Dated as of _______, 20__ Debt SecuritiesIndenture • July 27th, 2017 • Senomyx Inc • Services-commercial physical & biological research • New York
WHEREAS, for its lawful corporate purposes, the Company has duly authorized the execution and delivery of this Indenture to provide for the issuance of debt securities (hereinafter referred to as the “Securities”), in an unlimited aggregate principal amount to be issued from time to time in one or more series as in this Indenture provided, as registered Securities without coupons, to be authenticated by the certificate of the Trustee;
SENOMYX, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Warrant Agreement • July 31st, 2014 • Senomyx Inc • Services-commercial physical & biological research • New York
PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between SENOMYX, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
ANDLicense Agreement • February 21st, 2001 • Senomyx Inc • California
AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENTCommon Stock Warrant Agreement • July 27th, 2017 • Senomyx Inc • Services-commercial physical & biological research • New York
COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between SENOMYX, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
SENOMYX, INC. and MELLON INVESTOR SERVICES LLC as Rights Agent RIGHTS AGREEMENT Dated as of February 14, 2005Rights Agreement • February 15th, 2005 • Senomyx Inc • Services-commercial physical & biological research • New York
THIS RIGHTS AGREEMENT (“Agreement”), dated as of February 14, 2005, between SENOMYX, INC., a Delaware corporation (the “Company”), and MELLON INVESTOR SERVICES LLC (“Rights Agent”).
AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [__], 20___Preferred Stock Warrant Agreement • July 27th, 2017 • Senomyx Inc • Services-commercial physical & biological research • New York
PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between SENOMYX, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [__], 20___Debt Securities Warrant Agreement • July 27th, 2017 • Senomyx Inc • Services-commercial physical & biological research • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between SENOMYX, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
RECITALSIndemnification Agreement • February 21st, 2001 • Senomyx Inc • Delaware
BETWEEN SENOMYX, INC. ANDCollaborative Research and License Agreement • February 21st, 2001 • Senomyx Inc • California
7,142,857 Shares SENOMYX, INC. Common Stock ($0.001 Par Value) EQUITY UNDERWRITING AGREEMENTEquity Underwriting Agreement • February 16th, 2010 • Senomyx Inc • Services-commercial physical & biological research • New York
Senomyx, Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters (the “Underwriters”) named in Schedule I hereto for whom you are acting as representative (the “Representative” or “you”) an aggregate of 7,142,857 shares (the “Firm Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”). The respective amounts of the Firm Shares to be so purchased by the several Underwriters are set forth opposite their names in Schedule I hereto. The Company also proposes to sell at the Underwriters’ option an aggregate of up to 1,071,428 additional shares of the Company’s Common Stock (the “Option Shares”) as set forth below. The Firm Shares and the Option Shares (to the extent the aforementioned option is exercised) are herein collectively called the “Shares.”
SENOMYX, INC., Issuer AND U.S. BANK NATIONAL ASSOCIATION, TrusteeSenomyx Inc • October 6th, 2005 • Services-commercial physical & biological research • New York
INDENTURE, dated as of October 6, 2005, among SENOMYX, INC., a Delaware corporation (the “Company”), and U.S. Bank National Association, as trustee (the “Trustee”):
PURCHASE AGREEMENTPurchase Agreement • December 22nd, 2016 • Senomyx Inc • Services-commercial physical & biological research • Illinois
PURCHASE AGREEMENT (the “Agreement”), dated as of December 21, 2016, by and between SENOMYX, INC., a Delaware corporation (the “Company”), and LINCOLN PARK CAPITAL FUND, LLC, an Illinois limited liability company (the “Investor”).
CONFIDENTIALITY AGREEMENTConfidentiality Agreement • October 4th, 2018 • Senomyx Inc • Services-commercial physical & biological research • Delaware
THIS CONFIDENTIALITY AGREEMENT (“Agreement”) is being entered into as of April 13, 2018, between Senomyx, Inc. (the “Company”) and Firmenich, SA (“Counterparty”).
SENOMYX, INC. INDEMNITY AGREEMENTIndemnity Agreement • June 9th, 2004 • Senomyx Inc • Services-commercial physical & biological research • Delaware
THIS INDEMNITY AGREEMENT (this "Agreement") is made and entered into this day of , 2004 by and between SENOMYX, INC., a Delaware corporation (the "Company"), and ("Agent").
TEXT OMITTED AND FILED SEPARATELY CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTIONS 200.80(b)(4), 200.83 AND 230.406Collaborative Agreement • February 21st, 2001 • Senomyx Inc • California
11099 North Torrey Pines Road La Jolla, CA 92037 EXPANSION LEASE BY AND BETWEENExpansion Lease • February 21st, 2001 • Senomyx Inc • California
CHANGE IN CONTROL AGREEMENTChange in Control Agreement • February 23rd, 2007 • Senomyx Inc • Services-commercial physical & biological research • California
THIS CHANGE IN CONTROL AGREEMENT (the “Agreement”) is made as of October 10, 2006 between SENOMYX, INC., a Delaware corporation (the “Company”), and Sharon Wicker (“Employee”).
SUBLEASESublease • February 21st, 2001 • Senomyx Inc
SENOMYX, INC.And Inventions Agreement • February 21st, 2001 • Senomyx Inc • California
SENOMYX, INC. and , As Warrant Agent FORM OF DEBT SECURITIES WARRANT AGREEMENT Dated As OfSecurities Warrant Agreement • August 7th, 2008 • Senomyx Inc • Services-commercial physical & biological research • New York
DEBT SECURITIES WARRANT AGREEMENT (“Agreement”), dated as of between SENOMYX, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
EXHIBIT 10.21 AMENDED AND RESTATED SUBLEASE THIS AMENDED AND RESTATED SUBLEASE (this "Sublease") is dated as of July 17, 2000, and is made by and between Senomyx, Inc., a Delaware corporation, as successor in interest to Sequana Therapeutics, Inc....Sublease • February 21st, 2001 • Senomyx Inc
May 9, 2014 Catherine C. LeeAnd Inventions Agreement • March 3rd, 2016 • Senomyx Inc • Services-commercial physical & biological research • California
We are pleased to extend to you an offer to join Senomyx, Inc. (the “Company”) as our Vice President, General Counsel and Corporate Secretary. The following terms apply and will constitute your employment agreement with the Company (the “Agreement”).
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • June 9th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware Corporation having offices at 11099 North Torrey Pines Road, La Jolla, CA 92037 ("Senomyx") and KRAFT FOODS, INC., a Delaware Corporation having offices at 801 Waukegan Road, Glenview, IL 60025 ("Kraft").
FIRST AMENDMENT TO EMPLOYMENT AGREEMENTEmployment Agreement • December 23rd, 2008 • Senomyx Inc • Services-commercial physical & biological research
THIS FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is entered into effective as of December 31, 2008 (the “Effective Date”), by and between R. KENT SNYDER (the “Employee”) and SENOMYX, INC. (the “Company”).
AGREEMENT AND PLAN OF MERGER among: SENOMYX, INC., a Delaware corporation; FIRMENICH INCORPORATED, a Delaware corporation; and SENTRY MERGER SUB, INC., a Delaware corporation Dated as of September 16, 2018Agreement and Plan of Merger • September 17th, 2018 • Senomyx Inc • Services-commercial physical & biological research • Delaware
THIS AGREEMENT AND PLAN OF MERGER (“Agreement”) is made and entered into as of September 16, 2018, by and among: FIRMENICH INCORPORATED, a Delaware corporation (“Parent”); SENTRY MERGER SUB, INC., a Delaware corporation and a wholly owned subsidiary of Parent (“Purchaser”); and SENOMYX, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
Exclusive License and Bailment Agreement between The Regents of the University of California and Ambryx Inc. for "Nucleic Acids Encoding Proteins Used in Assays for Identifying Taste Modulators" UC Case Nos. 1998-122,1998-306,1999-0151...Senomyx Inc • June 9th, 2004 • Services-commercial physical & biological research • California
This license agreement (Agreement) is effective this 10th day of March, 2000 by and between The Regents of the University of California (The Regents), a California corporation, having its statewide administrative offices at 1111 Franklin Street, 12th floor, Oakland, CA 94607-5200, and Ambryx Inc. (Licensee), a Delaware corporation, having a principal place of business at 11099 North Torrey Pines Road Suite 160, La Jolla, CA 92037, herein referred to collectively as the parties (Parties).
August 25, 2003 Harry Leonhardt PO Box 3023 Rancho Santa Fe CA 92067 Dear Harry:Senomyx Inc • March 29th, 2004 • Services-commercial physical & biological research • California
We are pleased to extend to you an offer to join Senomyx, Inc. ("Company") as our Vice President and General Counsel. The following terms apply and will constitute your employment agreement with the Company (the "Agreement").
AND LICENSE AGREEMENTAnd License Agreement • February 2nd, 2010 • Senomyx Inc • Services-commercial physical & biological research
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware Corporation having offices at 4767 Nexus Centre Drive, San Diego, CA 92121, U.S.A. (“Senomyx”) and FIRMENICH SA, a Swiss Company, having its principal place of business at 1, route des Jeunes, 1211 Geneva 8, Switzerland (“Firmenich”).
AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN SENOMYX, INC. AND PEPSICO, INC.And License Agreement • March 21st, 2017 • Senomyx Inc • Services-commercial physical & biological research • Delaware
This Amended and Restated Agreement (the “Agreement”) is entered into as of September 30, 2016 (the “Amended Effective Date”) by and between SENOMYX, INC., a Delaware Corporation having its principal place of business at 4767 Nexus Centre Drive, San Diego, CA 92121 (“SENOMYX”) and PEPSICO, INC., a North Carolina Corporation, having its principal place of business at 700 Anderson Hill Road, Purchase, NY 10577 (“PEPSICO”).
STANDSTILL AGREEMENTStandstill Agreement • May 22nd, 2017 • Senomyx Inc • Services-commercial physical & biological research • Delaware
This STANDSTILL AGREEMENT (this “Agreement”) is made and entered into as of May 19, 2017, among Senomyx, Inc., a Delaware corporation (the “Company”), on the one hand, and each of Barry A. Igdaloff, VCM Group LLC, Lee D. Keddie, Benjamin E. Large, Gus D. Halas, David W. Pointer, Mark D. Stolper, and Charles M. Gillman (collectively, “CSNS”), on the other hand. The Company and CSNS are each referred to herein as a “Party” and collectively, as the “Parties.”
AMENDED AND RESTATED COLLABORATIVE RESEARCH, DEVELOPMENT, COMMERCIALIZATION AND LICENSE AGREEMENT BETWEEN SENOMYX, INC. AND FIRMENICH SAAnd License Agreement • March 8th, 2018 • Senomyx Inc • Services-commercial physical & biological research
THIS AMENDED AND RESTATED AGREEMENT is entered into as of February 7, 2018, by and between SENOMYX, INC., a Delaware Corporation having offices at 4767 Nexus Centre Drive, San Diego, CA 92121, U.S.A. (“Senomyx”) and FIRMENICH SA, a Swiss Company, having its principal place of business at 1, route des Jeunes, 1211 Geneva 8, Switzerland (“Firmenich”).
